AMD announced its first life sciences collaboration with AI-based drug developer Absci, providing its hardware and software for Absci’s AI drug discovery. Despite AMD also investing $20m in Absci, its shares fell 4% after HSBC analyst Frank Lee downgraded the firm from “Buy” to “Reduce” and cut its price target by 18%, suggesting AMD will continue trailing market leader Nvidia. This is AMD’s first life-sciences partnership.
Decision making and patient education enhanced by custom AI tools
The content mentions “Enterprise Taxonomy” related to AI Operations, Analytics, Business Data, and Information. It also specifies a setting to exclude this node from the
